Last reviewed · How we verify

Nitric oxide by inhalation INOMAX

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

Nitric oxide by inhalation INOMAX is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development. Also known as: INOMAX.

At a glance

Generic nameNitric oxide by inhalation INOMAX
Also known asINOMAX
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nitric oxide by inhalation INOMAX

What is Nitric oxide by inhalation INOMAX?

Nitric oxide by inhalation INOMAX is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes Nitric oxide by inhalation INOMAX?

Nitric oxide by inhalation INOMAX is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Nitric oxide by inhalation INOMAX also known as anything else?

Nitric oxide by inhalation INOMAX is also known as INOMAX.

What development phase is Nitric oxide by inhalation INOMAX in?

Nitric oxide by inhalation INOMAX is in Phase 2.

Related